

Tendon regeneration data presented at South African sports medicine meeting

- Positive 4.5 year follow up data for the treatment of recalcitrant tennis elbow injuries using Ortho-ATI™ presented at the 16th Biennial Congress of the South African Sports Medicine Association
- Positive two year follow up data for the treatment of recalcitrant gluteal tendinopathy in the hip using Ortho-ATI™ also presented at the 16th Biennial Congress of the South African Sports Medicine Association

Perth, Australia; 22 October 2015: Regenerative medicine company Orthocell Limited presented previously released positive data for the treatment of recalcitrant tendon injuries in the hip and the elbow at the South African Sports Medicine Association Biennial Scientific meeting in Johannesburg, South Africa, yesterday.

Positive 4.5 year mean follow up data for the treatment of recalcitrant tennis elbow injuries and positive two year follow up data for the treatment of long term gluteal tendon injuries in the hip were presented by Dr Jay Ebert, one of Australia's leading exercise physiologists.

Orthocell CEO Paul Anderson said: "Gluteal tendinopathy is a difficult to treat condition that has debilitating effects on a patient's daily life activities and even their ability to sleep. There are no clear solutions to fix this problem and Ortho-ATI™ has shown to be an effective and durable treatment targeting the underlying cause of the pain."

The gluteal study found Ortho-ATI™ demonstrated significant clinical improvement for recalcitrant gluteal tendinopathy to 12 months and maintained out to 24 months whilst the elbow study has demonstrated durable long term repair with 207% improvement in grip strength. The study results were published in the prestigious American Journal of Sports Medicine in April 2015.*

The South African Sports Medicine meeting brings together sports doctors from the region. The results Orthocell has achieved with its regenerative treatments and their presentation at key meetings of experts around the world demonstrates the quality of the company's research and the desire for clinicians to access an effective treatment for difficult to treat tendon injuries.

Transparency Market Research estimate that the US, Europe and Japan markets for tennis elbow treatment is estimated to be worth US\$700 million in 2015.

**Refer to ASX announcements 30/04/2015 and 16/10/2014 for further details relating to these studies.*

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au

Investor relations

Ben Walsh
Buchan Consulting
P: 0417 382 391
E: bwalsh@buchanwe.com.au

Media enquiries

Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.